Given the compelling preclinical data and biological rationale suggesting that PDE10A inhibition would positively impact schizophrenia, the clinical results from Pfizer, Takeda, and Lundbeck call for a reevaluation of our hypotheses regarding the mechanism(s) by which PDE10A inhibitors and D2 antagonists may ameliorate psychosis. Here, PDE10A is linked to psychotic disorder.